13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D/A Filed 2026-07-16 Event 2026-07-14 SEC 0001104659-26-084327 →

BAKER BROS. ADVISORS LP Celcuity Inc. CELC

Stake: 9.99% Shares: 4,877,963 CUSIP: 15102K100 Class: Common Stock, $0.001 par value per share

Item 4 — Purpose of Transaction

Item 4 of this Amendment No. 2 is supplemented and amended, as the case may be, as follows: The disclosures in Item 5 below are incorporated herein by reference. This Amendment No. 2 is being filed to report the sale of shares of the common stock ("Common Stock") of Celcuity Inc. (the "Issuer") reported in Item 5(c) that resulted in a more than 1% change in beneficial ownership. The disclosure regarding the sales in Item 5(c) below is incorporated herein by reference. Additionally, on July 14, 2026, the Adviser on behalf of the Funds submitted written notice to the Issuer to set the beneficial ownership limitation (the "Maximum Percentage") with respect to 481,437 and 5,666,350 prefunded warrants to purchase Common Stock at an exercise price of $0.001 per share (the "$0.001 Prefunded Warrants") held by 667 and Life Sciences, respectively, at 9.99%, effective immediately. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the board of directors and management of the Issuer, the availability and nature of opportunities to dispose of securities of the Issuer and other plans and requirements of the particular entities. Depending upon their assessments of the above factors, the Reporting Persons may acquire additional securities of the Issuer, including shares of Common Stock (by means of open market purchases, privately negotiated purchases, exercise of $0.001 Prefunded Warrants, conversion of 2.75% Convertible Notes (as defined in Item 5) or otherwise) or dispose of some or all of the securities of the Issuer, including shares of Common Stock, under their control. As a result of the dispositions of Common Stock reported in Item 5(c) and the setting of the Maximum Percentage at 9.99% described above, the Reporting Persons beneficially own less than 10% of the outstanding Common Stock, are not affiliates of the Issuer, and hold the securities of the Issuer for investment purposes and not with the purpose or effect of changing or influencing control of the Issuer. Accordingly, the Reporting Persons are eligible to report their beneficial ownership of the Common Stock on Schedule 13G and intend to report on Schedule 13G in future filings, subject to the applicable requirements of Rule 13d-1.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
64 filings by this filer
63 other filings in the data moat
Short Interest · settle 2026-06-30
DTC 8.56
10,969,220 shares short · +2.8% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $239K
Point72 Asset Mgmt

Other 13D/G Filings on Celcuity Inc.

FiledFormFilerStakeShares
2026-07-16 SCHEDULE 13G BAKER BROS. ADVISORS LP view →

Other Filings by BAKER BROS. ADVISORS LP

FiledFormIssuerStakeShares
2026-07-16 SCHEDULE 13G Celcuity Inc. view →
2026-06-15 SCHEDULE 13D/A BeOne Medicines Ltd. BEIGF 8.00% 115,457,154 view →
2026-05-26 SCHEDULE 13D/A Kiniksa Pharmaceuticals International, plc KNSA 7.00% 3,231,181 view →
2026-05-11 SCHEDULE 13D/A Incyte Corp INCY 30,865,077 view →
2025-06-30 SCHEDULE Kymera Therapeutics, Inc. KYMR 9.50% 6,666,540 view →
2024-10-08 SC Kiniksa Pharmaceuticals International, plc KNSA view →
2024-06-14 SC INCYTE CORP INCY view →
2023-12-18 SC Seagen Inc. view →
2023-10-10 SC Neoleukin Therapeutics, Inc. NGNE view →
2023-10-05 SC MADRIGAL PHARMACEUTICALS, INC. MDGL view →
2023-07-19 SC Neoleukin Therapeutics, Inc. NGNE view →
2023-05-24 SC ACADIA PHARMACEUTICALS INC ACAD view →
2023-05-24 SC Prelude Therapeutics Inc PRLD view →
2023-05-03 SC Seagen Inc. view →
2023-03-15 SC INCYTE CORP INCY view →
2023-03-13 SC Seagen Inc. view →
2023-01-17 SC ACADIA PHARMACEUTICALS INC ACAD view →
2022-07-20 SC Immunocore Holdings plc IMCR view →
2022-05-18 SC Kodiak Sciences Inc. KOD view →
2022-02-14 SC INCYTE CORP INCY view →
Showing 20 of 63

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →